drugset / Trial / NCT01127204

Summary

The MONOD trial aim to evaluate the implementation of early antiretroviral treatment strategies in HIV-infected infants and assess the feasibility and efficacy of simplifying the initial proposed regimen after a successful one year treatment. The initial treatment is AZT-3TC-LPV/r twice a day. After one year, the children will be randomized in one of the following : arm 1-reference AZT-3TC-LPV/r twice daily; arm 2-simplified ABC-3TC-EFV once daily. The perspective of this project is to identify antiretroviral strategies to improve treatment access and adherence for children in sub-saharian Africa.

Timeline

Start
2011-06
Primary completion
2015-04
Completion
2015-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZT Unknown 4 mg/kg
Comparator AZT Unknown 180 mg/m2
Subject Abacavir Other / unclassified 16 mg/kg
Subject Efavirenz Other / unclassified 25 mg/kg
Comparator LPV/r Unknown 12 mg/kg
Comparator Lamivudine Other / unclassified 4 mg/kg
Comparator Lamivudine Other / unclassified 8 mg/kg